Stay updated on Dostarlimab Combo in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Dostarlimab Combo in Endometrial Cancer Clinical Trial page.

Latest updates to the Dostarlimab Combo in Endometrial Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page revision tag has been updated from v3.6.6 to v3.7.0. This indicates a new build/patch of the ClinicalTrials.gov page, without affecting the study content or presentation.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page revision label was updated from v3.6.5 to v3.6.6, representing a new version of the page. This update likely reflects minor edits or metadata adjustments rather than a major content change.SummaryDifference0.0%

- Check26 days agoChange DetectedA new NIH grant/contract identifier was added to the study's list of other identifiers, indicating NIH funding attribution for the RUBY trial.SummaryDifference0.0%

- Check33 days agoChange DetectedThe author list in the Publications citation for the Dostarlimab NEJM paper has been deleted, altering the attribution shown for that study reference.SummaryDifference0.1%

- Check40 days agoChange DetectedA new NEJM publication citation for Dostarlimab in primary advanced or recurrent endometrial cancer was added, listing authors and article details. The page revision history was updated from v3.6.4 to v3.6.5.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4 on the page, signaling a recent internal update to the site's revision. No visible content or user-facing changes are indicated.SummaryDifference0.0%

Stay in the know with updates to Dostarlimab Combo in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dostarlimab Combo in Endometrial Cancer Clinical Trial page.